Study of RC48-ADC Administered Intravenously to Subjects With HER2-Positive in Advanced Malignant Solid Tumors
Status:
Completed
Trial end date:
2019-11-08
Target enrollment:
Participant gender:
Summary
A tolerance, safety and pharmacokinetic ascending dose phase I Study of RC48-ADC administered
intravenously to subjects with HER2-positive malignant in advanced malignant solid tumors.